Skip to main content

Are you Struggling with Coronary Heart Disease or an Abnormal ECG?

You might qualify for the Acute Coronary Syndrome (ACS) Research Study!

Acute Coronary syndrome (ACS) is an acute manifestation of coronary heart disease and one of the major causes of death for men and women in the United States. This often leads to a heart attack, stroke, or an unstable angina (heart pain).  

Despite advancements in medicine and treatments, there is still an unmet need for effective treatments that can reduce the risk of fatal and non-fatal myocardial infarction (MI).  

At Revival Research Institute, we are conducting a clinical research study evaluating the long-term safety profile of an investigational drug in people specifically with coronary heart disease.  

You may be eligible for the Clinical Research Study if you:

  • Are 45 years of age or above, male or female both
  • Have a history of recent acute coronary syndrome
  • Have a history of ECG abnormalities without biomarkers

Additional criteria may apply

Revival Research Institute is one of the many sites that is working in collaboration with the sponsor to conduct this groundbreaking research study. We’re working to evaluate how a potential investigative acute coronary syndrome treatment may be able to help reduce the risk of life-threatening heart-related complications. This Acute Coronary Syndrome Research Study will help Cardiologists and doctors gain a better understanding of the condition and observe whether the investigational medication helps to reduce fatal or non-fatal myocardial infarction.

*To participate in the research study, simply fill the form and someone from the research staff will get back to you shortly with a phone call. Your medical history will be collected by the research personnel. However, your information will not be disclosed to anyone outside of the organization, as stated in our Privacy Policy.

**Participating in the research study is free of cost to you and your insurance. You will not be charged in any capacity and will instead be provided with a stipend for every visit you make to the site, should you decide to participate in the study and if you qualify.

Please provide YOUR contact information only.

About Acute Coronary Syndrome Research Study

The Revival Research Institute in collaboration with sponsors is conducting a Coronary Heart Disease Research Study to observe the safety and effectiveness of a study drug that may be able to help people with coronary heart disease. This includes people suffering from recent acute coronary syndrome (ACS) or with an appropriate genetic profile.

The ACS Research Study may last anywhere between 4 to 5 years. Participants can expect study visits for the purpose of efficacy and safety assessments. In this study, every participant will be assigned to treatment groups in a 1:1 ratio which will help to lower the occurrence of fatal and non-fatal myocardial infarction. The study will last approximately 50 months (about 4 years) in total. Subjects will take 600 mg of both experimental and placebo medication once daily preferably along with the largest meal of the day.

The study is looking at the effects of an experimental drug on cardiovascular risk in a population with recent Acute Coronary Syndrome (ACS) and might work as a potential acute coronary syndrome treatment. You may be eligible to participate in the study if you meet the inclusion criteria.

*The study drug and study-related care is free of charge for volunteers who are eligible for the study. If you qualify, you will receive a call from someone on our research staff. You may be asked to share your personal information regarding your complete medical history, overall health, and any medication you take.

*All volunteers who may be eligible for the research study will receive the study drug and study-related care, free of cost. And you may be compensated for your time and travel. No insurance is required to participate.

Get Started: What to Expect?

If you qualify and decide to take part in the ACS study, you will first need to sign the Informed Consent Form. The study team will walk you through the process and discuss in detail your participation in the research study. It is entirely your decision whether or not you decide to take part in the research study. We encourage all participants to ask as many questions as they’d like about the clinical trial.

Once you sign the consent form and meet all the study requirements, you will be assigned to one of two study groups by random chance. Every participant has an equal chance (50%) of being assigned to either one of the study groups. One of the study groups will receive the placebo (medication without the active ingredient of the study drug) and the other group will receive the experimental drug. The study team will not know which medication you receive as this is a double-blind research study. However, your study doctor can learn which you have been assigned to in case there is an emergency.

*Participation in the research study is completely voluntary. Every participant has the right to withdraw from the study at any time for the duration of the study.


Acute Coronary Syndrome (ACS)

Length of Study

Approx. 4 years

Number of Study Visits

3 onsite visits & after every 3 months virtual or onsite visits

About Acute Coronary Syndrome (ACS)

Acute Coronary Syndrome Clinical Trials

Acute Coronary Syndrome (ACS) is a medical term for critical coronary artery diseases that affect millions of people. It is characterized by a sudden decrease in blood flow or when the blood supplied is completely stopped.

ACS occurs due to the rupture of arterial plaques, which results in blood clot formation and can adversely affect the blood supply to the heart.


Acute coronary syndrome symptoms typically appear suddenly, sometimes without warning. Severe chest pain or discomfort characterizes ACS. It’s a medical emergency that necessitates immediate diagnosis and treatment. Other signs and symptoms include:

  • Back, jaw, neck, or stomach pain in one or both arms
  • Breathing problems
  • Lightheadedness or dizziness
  • Indigestion
  • Nausea or vomiting
  • Sweating



In some cases, acute coronary syndrome can be avoided. Acute coronary syndrome is caused by heart disease, but those who do not have it can protect themselves by eating a heart-healthy diet, quitting smoking, drinking alcohol in moderation, being active, and maintaining a healthy weight.

Am I At Risk?

People should be aware of various risk factors linked with acute coronary syndrome. Some of the risk factors include being over the age of 45, living with cholesterol or blood pressure problems, smoking, insufficient physical activity, obesity, diabetes, and having a family history of the condition.

Frequently Asked Questions

What is Acute Coronary Syndrome?

Acute coronary syndrome (ACS) is a group of symptoms and signs caused by a blockage in the coronary arteries. Chest discomfort, dyspnea, and electrocardiographic irregularities are common signs and symptoms. A blockage of the coronary artery due to cholesterol-rich plaque and thrombus is the most prevalent cause of the acute coronary syndrome.

Why is the ACS trial being done?

After a heart attack, the risk of complications is high. The ACS clinical trial explores a new medication to offer additional protection during this critical period.

How to prevent repeat attacks?

People who have suffered from heart attacks are at higher risk for repeat attacks. However, participating in clinical trials can provide a potential investigative treatment option for all those who want to live a normal life after ACS.

Is the incidence the same for males and females?

Men are more prone than women to develop coronary artery disease and have heart attacks earlier in life. After menopause, a woman’s risk of heart attack rises.

What is a double-blind research study?

The Acute Coronary Syndrome clinical trial is an example of a double-blind study. This means that there are two groups assigned to the research study. One will receive the placebo (medication without the active ingredient) and the other will receive the study drug. Neither you nor the research staff, including the study doctor, will know which group you’ve been assigned to. Every participant has an equal chance (50%) of being assigned to either one of the two groups.

Close Menu